Abstract
During the Covid-19 pandemic, Denmark has pursued a unique mass testing strategy culminating in testing of more than 8,000 citizens per 100,000 inhabitants per day in the Spring 2021. The strategy includes free access to Covid-19 testing and since 2021, compulsory documentation for negative test or vaccination for access to workplace, educational institutions, restaurants, and many other places.
In the present study we analysed the effect of the Danish mass testing strategy throughout relevant stages of the pandemic. Mass testing was found not to have impact on the number of hospitalizations during the pandemic. Furthermore, during the highest level of testing in the spring 2021 the fraction of positive tests increased slightly on comparable days indicating that mass testing at best, did not reduce the prevalence of Covid-19.
The relationship between positives in antigen testing and in PCR testing indicated that many patients are not tested early in their infection where the risk of transmission is highest.
A likely explanation for the lack of impact of mass testing on hospitalizations and infections is that the testing increases risk-behaviour of the tested persons and that a high fraction of false negatives at low Covid-19 prevalence combined with increased risk-behaviour outweighs beneficial effects of mass testing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Danish Ministry of Health LBK nr 903 af 26/08/2019
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available.
